Accurate Education - Module 2: PRE-Operative Nutraceutical Management

Peri-operative Pain Management:

Module 2:

PRE-Operative Nutraceutical Management

This section covers Module 2 of the Peri-operative Pain Protocol — Pre-operative Nutraceutical Management — as part of a comprehensive approach to the management of pain associated with upcoming, planned surgical procedures. These procedures include those for the management of chronic joint, neck and back pain such as spinal fusions, artificial disc replacements, total joint replacements as well as less invasive procedures.

Perioperative – Before, During and After Surgery
Preoperative – Before Surgery
Postoperative – After Surgery

This guide is not intended to replace appropriate nutritional guidance that should be provided by a dietitian regarding perioperative dietary management. Please consult with your surgeon for dietary guidance including referral to a dietitian.

See:

Peri-Operative Pain Management (P-OPM)

Key to Links:

Grey text – handout
Red text – another page on this website
Blue text – Journal publication

Definitions and Terms Related to Pain

Module 2:

PRE-Operative Nutraceutical Management

Introduction – The Peri-Operative Pain Management Protocol

The goal of the peri-operative pain protocol is to manage pain starting with the pre-operative period (4–6 weeks before surgery) through the post-operative period (up to 12 weeks after surgery. This protocol includes dietary & nutritional management as well as the use of nutraceuticals during both the pre-operative and post-operative periods. It is designed to reduce not only post-operative pain, but importantly, to also reduce the transitioning of post-operative pain from becoming chronic pain.

This peri-operative pain management protocol applies the principles of the 4-D chronic pain management protocols described here.The 4-D protocols engage lifestyle management as well as the use of prescription medications and therapeutic nutraceuticals based on the anti-inflammatory diet.

Strategic Framework for Protocol Development – A Modular Approach

Protocol Structure and Development Sequence

The peri-operative protocol is divided into the pre-operative period (4–6 weeks before surgery) and the post-operative period ((0–12 weeks after surgery). The pre-operative and post-operative protocols are each divided into two modules (1) Dietary & Nutritional Management and (2) Nutraceutical Management.

The four modules are presented in this order, as each builds on the prior:

Pre-operative Management (4–6 weeks before surgery)

Module 1: Dietary and Nutritional Management
Module 2: Nutraceutical Management

Post-operative Management (0–12 weeks after surgery)

Module 3: Dietary and Nutritional Management
Module 4: Nutraceutical Management

Outlined in the protocol are breakdowns of the responsibilities for both the surgical team and the pain management team regarding the assessment and management of the patient’s pain. Topics include pre-operative and post-operative dietary & nutritional management and recommended nutraceutical management.

Peri-operative Considerations for Patients on Chronic Opioid Management

Of note, this protocol has been established to facilitate appropriate and effective peri-operative pain management specifically directed at those pain patients who have been taking opioids chronically for their pain. Both the presence of chronic pain, as well as the long-term use of opioids, introduces significant variables that impact appropriate choices for managing the patient’s pain. An additional section is forthcoming for the management of peri-operative pain management directed at those patients with acute pain and/or non-opioid dependent pain.

Module 2

Module 2 of the peri-operative protocol — the Pre-operative Nutraceutical Management Protocol – . maps each of the 4-D Protocol’s 20 nutraceuticals to specific peri-operative timelines based on the SPAQI Consensus Statement. It integrates the 4-D domain-profiling logic, and provides a phased approach to pre-operative nutraceutical optimization that accounts for both therapeutic benefit and surgical safety.

OVERVIEW AND RATIONALE

This module provides a structured protocol for managing the 4-D Protocol’s nutraceuticals during the preoperative period in chronic pain patients on long-term opioid therapy scheduled for elective orthopedic surgery.

This protocol serves two simultaneous objectives:

1. Maximize the preoperative anti-inflammatory, antioxidant, and neuroprotective priming window (4–6 weeks before surgery) to optimize the patient’s biochemical milieu entering surgery.

2. Ensure peri-operative safety by adhering to evidence-based hold timelines, primarily derived from the SPAQI Consensus Statement on Preoperative Management of Dietary Supplements.[1]

The fundamental tension in this module is that many of the nutraceuticals most beneficial for pre-operative optimization (curcumin, resveratrol, quercetin, boswellia) must be held 2 weeks before surgery due to potential bleeding or other perioperative concerns. The protocol therefore employs a three-phase pre-operative timeline that maximizes the therapeutic window while respecting safety constraints.

—

SECTION 1: THREE-PHASE PRE-OPERATIVE TIMELINE

Phase 1: Optimization Window (6 to 2 weeks before surgery)

This is the primary therapeutic window. All 4D Protocol nutraceuticals that are indicated by the patient’s domain profile are initiated or continued at full therapeutic doses. The goal is to achieve maximal anti-inflammatory priming, oxidative stress reduction, and neuroinflammatory modulation before the hold period begins.

Duration: 4 weeks (ideally initiated at the first preoperative visit, 6 weeks before surgery; minimum 2 weeks of optimization before the hold period).

Phase 2: Hold Period (2 weeks to 24 hours before surgery)

Nutraceuticals with identified perioperative risks are discontinued according to the SPAQI-recommended timelines. Only nutraceuticals with demonstrated perioperative safety or active perioperative benefit continue through this phase.

Duration: 2 weeks (aligned with the standard preoperative clinic visit timing).

Phase 3: Day of Surgery

Only nutraceuticals explicitly cleared for continuation are taken on the morning of surgery (with a sip of water per anesthesia protocol). All others are held.

—

SECTION 2: NUTRACEUTICAL CLASSIFICATION BY PERI-OPERATIVE ACTION

Each of the 4D Protocol’s nutraceuticals is classified below according to its peri-operative management recommendation. Classifications are based on the SPAQI Consensus Statement where available, supplemented by pharmacologic reasoning and available safety data for agents not specifically addressed by SPAQI.

Category A: CONTINUE Through Surgery

These nutraceuticals have demonstrated perioperative safety and/or active perioperative benefit. They should be continued throughout all three phases.

1. Omega-3 (EPA/DHA) — SPAQI: Continue. Prior concerns about bleeding risk have not been borne out in prospective studies. Perioperative benefit: Preoperative omega-3 supplementation reduces postoperative pain (VAS 10.9 vs. 25 mm, p = 0.015) and CRP levels at 24 hours post-surgery in an RCT. Continue at 2–4 g/day EPA/DHA. This is the single most important nutraceutical to maintain through surgery given its dual anti-inflammatory and analgesic properties.[1][2]

2. Melatonin — SPAQI: Continue. A Cochrane review concluded that preoperative melatonin reduces anxiety compared to placebo and may be as effective as midazolam. Available evidence demonstrates melatonin is safe in the perioperative period and may decrease delirium in hospitalized elderly patients. Continue at current dose (typically 3–10 mg nightly). Particularly valuable in this population given opioid-related sleep disruption.[1]

3. Vitamin D3 — Not specifically addressed by SPAQI as a “dietary supplement” concern; classified as a vitamin/nutrient. Deficiency/Suboptimal levels should be addressed with 50,00-0 IU weekly and subsequently monitored. Optimal levels should be maintained, continue at maintenance dose (2,000 – 5,000 IU/day) through surgery. Vitamin D deficiency predisposes to worse outcomes following spine surgery, and preoperative optimization reduces total complications. Orthopedic surgery itself causes acute vitamin D depletion, making preoperative adequacy even more critical.[3][4][5]

4. B-Complex Vitamins (including B12) — Not specifically addressed by SPAQI as a perioperative concern. Screening for MTHFR/methylation inadequacies with serum levels of homocysteine and methylmalonic acid (MMA) should be performed to confirm sufficient B Vitamin activation. Methylated forms of B vitamins should be provided as needed (e.g. Enlyte). Continue through surgery. Thiamine (B1) and magnesium are co-factors for key enzymes in intermediary metabolism, and surgery triggers increased requirement for thiamine-dependent enzyme activity during the systemic inflammatory response. B12 supplementation has been shown to improve short-term functional and mental health outcomes and decrease neuropathic analgesic consumption postoperatively.[6][7]

5. P5P (Pyridoxal-5′-Phosphate, active B6) — Continue through surgery as part of B-complex support. Essential for neurotransmitter synthesis (serotonin, norepinephrine, GABA) relevant to descending pain modulation pathways.

6. Magnesium — Continue through surgery. Peri-operative magnesium acts as an NMDA receptor antagonist and calcium channel blocker, dampening excitatory neurotransmission and reducing central sensitization. Trials and meta-analyses report that patients receiving peri-operative magnesium experience lower pain scores and need fewer opioids in the first 24–48 hours after surgery. Orthopedic surgery causes acute serum magnesium depletion — 40% of knee arthroplasty patients had low serum magnesium by postoperative day 1 (vs. 14% preoperatively). Continue oral magnesium glycinate at current dose (400–800 mg elemental Mg/day). Consider magnesium L-threonate as an alternative with greater CNS penetration. Note: The surgical team may also administer IV magnesium sulfate peri-operatively as part of multimodal analgesia — oral supplementation is complementary, not duplicative.[8][9][6]

Category B: HOLD 24 HOURS Before Surgery

These nutraceuticals have short-acting effects that warrant brief discontinuation.

7. NAC (N-Acetylcysteine) — SPAQI: Hold 24 hours. Concern relates to theoretical potential for increased nitric oxide synthase production, which could increase intra-operative hypotension risk. An RCT of pre-emptive IV NAC (150 mg/kg) for postoperative pain found no significant pain reduction and a high rate of anaphylactoid reactions (>50% of patients), arguing against IV use; however, oral NAC at standard doses (600–1,200 mg/day) has a different risk profile. Resume oral NAC on post-operative day 1 when hemodynamically stable. NAC’s role as a glutathione precursor makes early posto-perative resumption valuable for oxidative stress management.[1][10]

Category C: HOLD 2 WEEKS Before Surgery

These nutraceuticals have identified peri-operative risks (primarily bleeding, cardiovascular effects, or glucose metabolism effects) that warrant a 2-week hold period. They should be used at full therapeutic doses during Phase 1 (6 to 2 weeks before surgery) and then discontinued.

8. Curcumin — SPAQI: Hold 2 weeks. Inhibits platelet aggregation via thromboxane metabolism and calcium channel inhibition; also inhibits generation of thrombin and factor Xa. This is particularly important for spine fusion and procedures where bleeding would be dangerous. Preclinical data suggest curcumin alleviates postoperative pain and promotes recovery when given after surgery, though preoperative administration did not show preventive value. Maximize dose during Phase 1 for anti-inflammatory priming; plan for early postoperative restart (Module 4).[1][11]

9. Resveratrol — SPAQI: Hold 2 weeks. May have antiplatelet effect via inhibition of a COX pathway or by inhibiting cellular calcium channels. Discontinue at 2 weeks preoperatively. Resume postoperatively when hemostasis is assured.[1]

10. Quercetin — SPAQI: Hold 2 weeks. Shows anti-inflammatory effects; listed under supplements with multiple potential effects or drug interactions. Discontinue at 2 weeks preoperatively.[1]

11. Boswellia — Not specifically listed in the SPAQI 83-supplement table. However, boswellic acids inhibit 5-lipoxygenase and microsomal prostaglandin E synthase-1, with anti-inflammatory mechanisms similar to NSAIDs. Given the absence of perioperative safety data and the conservative SPAQI default recommendation of 2 weeks for supplements without sufficient data, hold 2 weeks before surgery. Boswellia has demonstrated pain reduction in osteoarthritis, supporting its use during Phase 1.[12][1][13]

12. CoQ10 (Coenzyme Q10) — SPAQI: Hold 2 weeks. Fat-soluble antioxidant and cofactor in mitochondrial electron transport. May cause hypotension by increasing nitric oxide production. This is a significant consideration for the 4D Protocol’s mitochondrial dysfunction domain. Maximize CoQ10 during Phase 1 to optimize mitochondrial reserves entering surgery; hold at 2 weeks.[1]

13. Alpha-Lipoic Acid (ALA) — SPAQI: Hold 2 weeks. Listed under supplements that may affect blood glucose — inhibits glucose absorption and increases insulin secretion, with potential for perioperative hypoglycemia. Preclinical studies suggest ALA decreases cold allodynia and pain, supporting its use in the chronic pain population during Phase 1. Hold at 2 weeks; if patient did not stop, surgery may proceed with close glucose monitoring.[1][7]

14. Sulforaphane — Not specifically listed in the SPAQI table. Sulforaphane (from broccoli sprout extract) activates the Nrf2 antioxidant pathway. Given the absence of perioperative safety data, apply the conservative SPAQI default of hold 2 weeks. Low perioperative risk profile based on mechanism, but insufficient data to recommend continuation.[1]

15. Acetyl-L-Carnitine (ALC) — Not specifically listed in the SPAQI table. ALC supports mitochondrial fatty acid transport and has demonstrated neuroprotective and analgesic properties. No known bleeding, cardiovascular, or glucose effects. Apply conservative SPAQI default of hold 2 weeks given absence of perioperative data.[1]

16. Nicotinamide Riboside (NR) / NAD+ Precursors — Not specifically listed in the SPAQI table. NR raises NAD+ levels and may reduce inflammatory states. No known perioperative risks identified in the literature. Apply conservative SPAQI default of hold 2 weeks.[14]

17. D-Ribose — Not specifically listed in the SPAQI table. D-Ribose supports ATP synthesis and mitochondrial energy production. May affect blood glucose levels (it is a sugar). Apply conservative SPAQI default of hold 2 weeks, with particular attention to glucose monitoring if not held.[1]

18. Taurine — Not specifically listed in the SPAQI table. Taurine is an amino acid with antioxidant and neuromodulatory properties. No known bleeding or cardiovascular concerns at standard doses. Apply conservative SPAQI default of hold 2 weeks given absence of perioperative data.

19. Agmatine — Not specifically listed in the SPAQI table. Agmatine is a decarboxylation product of arginine with NMDA receptor antagonist and imidazoline receptor agonist properties. Given its derivation from arginine and potential for nitric oxide modulation (similar to L-arginine, which SPAQI recommends holding 24 hours), a conservative hold of 2 weeks is recommended. Agmatine’s NMDA antagonist properties are mechanistically relevant to central sensitization prevention, making it a priority for early postoperative restart.[1]

20. PEA (Palmitoylethanolamide) — Not specifically listed in the SPAQI table. PEA is an endogenous fatty acid amide with anti-inflammatory and analgesic properties mediated through PPAR-α activation and endocannabinoid system modulation. Meta-analyses demonstrate significant pain reduction across nociceptive, neuropathic, and nociplastic pain types, with an excellent safety profile — no serious adverse drug reactions at an incidence of 1/200 or greater for treatment up to 49 days. PEA has no known antiplatelet, cardiovascular, or glucose effects. Its mechanism (PPAR-α agonism, mast cell modulation, glial cell regulation) does not overlap with identified peri-operative risk categories. Clinical judgment recommendation: PEA may reasonably be continued through surgery given its favorable safety profile and absence of identified perioperative risks, though this represents a clinical judgment call rather than a SPAQI-endorsed recommendation. If a conservative approach is preferred, hold 2 weeks per the SPAQI default.[15][16][17][18]

—

SECTION 3: MASTER PERI-OPERATIVE NUTRACEUTICAL SCHEDULE

The following table provides a consolidated view of the perioperative management of all 20 nutraceuticals:PEA: Continue or hold per clinical judgment; see Section 2 discussion.

OS = Oxidative Stress; Neuro = Neuroinflammation

Master PRE-Operative Nutraceutical Schedule

Nutraceutical	4D Domain(s)	Phase 1 6–2 wks preop	Phase 2 2 wks–24 hrs pre-op	Phase 3 Day of Surgery	Basis	References
Omega-3 (EPA/DHA)	Inflammation	✓ Full dose	✓ Continue	✓ Continue	SPAQI: Continue	[1], [2]
Melatonin	Neuroinflammation	✓ Full dose	✓ Continue	✓ Continue	SPAQI: Continue	[1]
Vitamin D3	Inflammation / Bone	✓ Full dose	✓ Continue	✓ Continue	Vitamin/nutrient	[3], [4], [5]
B-Complex (incl. B12)	Neuroinflammation	✓ Full dose	✓ Continue	✓ Continue	Vitamin/nutrient	[3], [6], [7]
P5P (active B6)	Neuroinflammation	✓ Full dose	✓ Continue	✓ Continue	Vitamin/nutrient	—
Magnesium	All 4 domains	✓ Full dose	✓ Continue	✓ Continue	Periop benefit	[7], [8], [9]
PEA	Neuroinflammation	✓ Full dose	✓ Continue	✓ Continue	Clinical judgment	[10], [11], [12]
NAC	Oxidative Stress	✓ Full dose	✓ Until 24 hrs preop	✗ Hold	SPAQI: Hold 24 hrs	[1]
Curcumin	Inflammation	✓ Full dose	✗ Hold	✗ Hold	SPAQI: Hold 2 wks	[1], [13]
Resveratrol	Oxidative Stress	✓ Full dose	✗ Hold	✗ Hold	SPAQI: Hold 2 wks	[1]
Quercetin	Inflammation / OS	✓ Full dose	✗ Hold	✗ Hold	SPAQI: Hold 2 wks	[1]
Boswellia	Inflammation	✓ Full dose	✗ Hold	✗ Hold	Conservative default	[1], [14]
CoQ10	Mitochondrial	✓ Full dose	✗ Hold	✗ Hold	SPAQI: Hold 2 wks	[1]
Alpha-Lipoic Acid	OS / Mitochondrial	✓ Full dose	✗ Hold	✗ Hold	SPAQI: Hold 2 wks	[1], [6]
Sulforaphane	Oxidative Stress	✓ Full dose	✗ Hold	✗ Hold	Conservative default	[1]
Acetyl-L-Carnitine	Mitochondrial	✓ Full dose	✗ Hold	✗ Hold	Conservative default	[1]
Nicotinamide Riboside	Mitochondrial	✓ Full dose	✗ Hold	✗ Hold	Conservative default	[1], [15]
D-Ribose	Mitochondrial	✓ Full dose	✗ Hold	✗ Hold	Conservative default	[1]
Taurine	OS / Neuro	✓ Full dose	✗ Hold	✗ Hold	Conservative default	[1]
Agmatine	Neuroinflammation	✓ Full dose	✗ Hold	✗ Hold	Conservative (arginine analog)	[1]

Master POST-Operative Nutraceutical Restart Schedule

Rec.	Nutraceutical	4D Domain(s)	POD 0–2	Days 7–14	Weeks 2–4	Weeks 4–12	Restart Priority	Ref.
	Omega-3 (EPA/DHA)	Inflammation	✓ Continue	✓	✓	✓	Continuous	[1]
	Melatonin	Neuroinflammation	✓ Continue	✓	✓	✓	Continuous	[1]
	Vitamin D3	Inflammation/Bone	✓ Continue	✓	✓	✓	Continuous	[2], [3]
	B-Complex (incl. B12)	Neuroinflammation	✓ Continue	✓	✓	✓	Continuous	[4], [5]
	P5P	Neuroinflammation	✓ Continue	✓	✓	✓	Continuous	—
	Magnesium	All 4 domains	✓ Continue	✓	✓	✓	Continuous	[6], [7], [8]
	PEA	Neuroinflammation	✓ Continue*	✓	✓	✓	Continuous or Phase B	[8]
	NAC	Oxidative Stress	✓ Restart POD 1	✓	✓	✓	Tier 1	[1]
	Curcumin	Inflammation	✗	✓ Restart	✓	✓	Tier 2 — HIGH	[9], [10], [11], [12]
	Resveratrol	Oxidative Stress	✗	✓ Restart	✓	✓	Tier 2	[13]
	Quercetin	Inflammation/OS	✗	✓ Restart	✓	✓	Tier 2	[13]
	Boswellia	Inflammation	✗	✓ Restart	✓	✓	Tier 2	[14]
	Sulforaphane	Oxidative Stress	✗	✓ Restart	✓	✓	Tier 2	—
	Taurine	OS/Neuro	✗	✓ Restart	✓	✓	Tier 2	—
	Agmatine	Neuroinflammation	✗	✓ Restart	✓	✓	Tier 2 — HIGH	—
	CoQ10	Mitochondrial	✗	✗	✓ Restart	✓	Tier 3	[15]
	Alpha-Lipoic Acid	OS/Mitochondrial	✗	✗	✓ Restart	✓	Tier 3	[16]
	Acetyl-L-Carnitine	Mitochondrial	✗	✗	✓ Restart	✓	Tier 3	—
	Nicotinamide Riboside	Mitochondrial	✗	✗	✓ Restart	✓	Tier 3	[8]
	D-Ribose	Mitochondrial	✗	✗	✓ Restart	✓	Tier 3	—

[34][35][36][24][37][41][46][47][19][42][43][44][45][38][39][40][26][25][28]

PEA: Continuous if continued through surgery per Module 2; restart in Phase B if held.

SECTION 4: DOMAIN-GUIDED PRIORITIZATION DURING PHASE 1

Not all patients will be on all 20 nutraceuticals. The 4-D Protocol’s individualized domain profiling determines which agents are indicated for each patient. During the preoperative optimization window (Phase 1), the following prioritization framework applies:

Priority Tier 1: Universal Preoperative Nutraceuticals (All Patients)

These should be initiated or confirmed in all surgical patients regardless of domain profile, based on perioperative evidence:

Omega-3 (EPA/DHA) 2–4 g/day — anti-inflammatory priming, postoperative pain reduction[2]
Vitamin D3 — repletion if deficient; maintenance if adequate[3][4]
Magnesium (glycinate or -threonate) 400–800 mg/day elemental — NMDA antagonism, central sensitization prevention, perioperative analgesic benefit[8][9]
B-Complex with B12 — neurotransmitter synthesis support, thiamine for surgical metabolic demand[5][6]
Melatonin 3–10 mg nightly — anxiolysis, sleep optimization, potential delirium prevention[1]

Priority Tier 2: Domain-Specific Agents (Based on 4D Profile)

Selected based on the patient’s individualized domain assessment:

Systemic Inflammation dominant: Curcumin (Phase 1 only), Boswellia (Phase 1 only), Quercetin (Phase 1 only) — maximize anti-inflammatory priming during the 4-week window before the hold period
Neuroinflammation dominant: PEA (may continue through surgery), Agmatine (Phase 1 only), P5P
Oxidative Stress dominant: NAC (hold 24 hrs only), ALA (Phase 1 only), Resveratrol (Phase 1 only), Sulforaphane (Phase 1 only)
Mitochondrial Dysfunction dominant: CoQ10 (Phase 1 only), ALC (Phase 1 only), NR (Phase 1 only), D-Ribose (Phase 1 only)

—

Priority Tier 3: Synergy Considerations

The 4-D Protocol recognizes synergy relationships between nutraceuticals. During Phase 1, key synergistic combinations to consider include:

Nutraceutical – Nutraceutical

Curcumin + Omega-3: Complementary anti-inflammatory pathways (COX/LOX inhibition + resolvin production)
NAC + ALA: Dual antioxidant support (glutathione synthesis + mitochondrial antioxidant)
Magnesium + Melatonin: NMDA antagonism + sleep/circadian optimization
PEA + Omega-3: Endocannabinoid system support + anti-inflammatory synergy

Opioids – Nutraceuticals

Gabapentinoids – Nutraceuticals

SNRIs – Nutraceuticals

Cannabinoids (THC) – Nutraceutical

SECTION 5: SPECIAL CONSIDERATIONS FOR SPINE FUSION AND HIGH-BLEEDING-RISK PROCEDURES

The SPAQI Consensus Statement specifically identifies spine fusion as a procedure “in which bleeding would be dangerous,” noting that postponing may be warranted if supplements with bleeding risk were not held.[1]

For patients undergoing spine fusion:

Strict adherence to the 2-week hold for all Category C nutraceuticals is essential. This includes curcumin, resveratrol, quercetin, and boswellia — all of which have antiplatelet or anticoagulant mechanisms.
If a patient presents for spine fusion having continued a bleeding-risk supplement, an individualized discussion between the surgeon, anesthesiologist, and pain management physician is recommended. Postponement may be the safest course.[1]
For total joint arthroplasty (TKA, THA), the bleeding risk is generally lower, and cautiously proceeding with surgery is likely reasonable if supplements were not held, though adherence to the hold schedule remains the standard recommendation.[1]

—

SECTION 6: MANAGING THE “HOLD GAP” — MAINTAINING DOMAIN COVERAGE DURING PHASE 2

A significant clinical concern is that holding 13 of 20 nutraceuticals for 2 weeks before surgery creates a therapeutic gap precisely when preoperative optimization is most critical. The following strategies mitigate this gap:

6A. Category A Agents Provide Continuous Coverage

The 7 agents that continue through surgery (omega-3, melatonin, vitamin D3, B-complex, P5P, magnesium, and potentially PEA) provide coverage across all four domains:

Systemic Inflammation: Omega-3, Vitamin D3
Neuroinflammation: Melatonin, B-complex, P5P, PEA, Magnesium
Oxidative Stress: Magnesium (indirect), B vitamins (methylation support)
Mitochondrial Dysfunction: Magnesium (cofactor), B vitamins (electron transport chain support)

6B. Dietary Intensification During Phase 2

When nutraceutical agents are held, the anti-inflammatory dietary pattern from Module 1 becomes even more important. During Phase 2, emphasize:

Increased fatty fish intake (additional omega-3 from food sources)
Turmeric and ginger in cooking (dietary levels, not supplement doses — dietary turmeric as a culinary spice is not subject to the supplement hold recommendation)
Increased berry and dark leafy green consumption (dietary polyphenols and flavonoids)
Green tea consumption (SPAQI notes green tea extract may be continued; green tea as a beverage is safe)[1]

6C. NAC Provides Near-Continuous Oxidative Stress Coverage

NAC requires only a 24-hour hold, making it the most continuously available oxidative stress agent. It can be continued through Phase 2 until the day before surgery, providing glutathione precursor support almost to the point of surgical incision.[1]

—

SECTION 7: DOCUMENTATION FOR SURGICAL TEAM

At the completion of the preoperative nutraceutical management plan, generate a supplement management summary for the surgical record that includes:

1. Complete list of nutraceuticals the patient is taking with doses

2. Date each held nutraceutical was discontinued

3. Nutraceuticals continuing through surgery (Category A list)

4. NAC hold date (24 hours preoperatively)

5. Any nutraceuticals the patient was unable or unwilling to hold, with risk assessment

6. Planned postoperative restart timeline (to be detailed in Module 4)

This document should accompany the surgeon communication letter (to be developed as a companion document) and the nutritional assessment summary from Module 1.

—

SECTION 8: INTEGRATION WITH MODULE 1 TIMELINE

The nutraceutical management protocol integrates with the Module 1 dietary/nutritional assessment as follows:

Visit 1 (6 weeks preoperatively):

Complete 4-D domain profiling (if not recently done)
Review current nutraceutical regimen
Initiate any new nutraceuticals indicated by domain profile (Phase 1 begins)
Initiate dietary interventions (Module 1)
Order laboratory panel (Module 1)

Visit 2 (4 weeks preoperatively):

Review lab results; adjust nutraceutical doses based on biomarker response
Reinforce dietary adherence
Prepare patient for upcoming hold period — provide written hold schedule with specific dates

Hold Date (2 weeks preoperatively):

Patient discontinues all Category C nutraceuticals
Continues Category A nutraceuticals and NAC
Intensifies dietary anti-inflammatory pattern (Section 6B)
This typically coincides with the preoperative surgical clinic visit, providing an opportunity to communicate the supplement management plan to the surgical team

Day Before Surgery:

Hold NAC (Category B — 24-hour hold)
Continue all Category A nutraceuticals

Day of Surgery:

Take Category A nutraceuticals with a sip of water per anesthesia protocol
All Category B and C nutraceuticals are held

Evidence Summary and Key Considerations

This module is anchored by the SPAQI Consensus Statement, which provides the most comprehensive evidence-based guidance for perioperative supplement management, covering 83 supplements using a modified Delphi method.[1] Of the 20 nutraceuticals in the 4D Protocol, 9 are directly addressed by SPAQI (omega-3, melatonin, curcumin/turmeric, resveratrol, quercetin, CoQ10, alpha-lipoic acid, NAC, and agmatine’s parent compound L-arginine), while the remaining 11 require extrapolation from pharmacologic principles and the SPAQI’s stated conservative default of a 2-week hold when insufficient data are available.[1]

The decision to continue omega-3 fatty acids through surgery is strongly supported — SPAQI explicitly states that “prior concerns about bleeding risk have not been borne out in prospective studies”, and an RCT demonstrated that preoperative omega-3 supplementation reduced postoperative pain by more than 50% and significantly lowered CRP at 24 hours post-surgery.[1][2]

Melatonin continuation is supported by a Cochrane review demonstrating perioperative anxiolysis comparable to midazolam, with an excellent safety profile and potential delirium prevention benefit.[1]

Magnesium continuation is supported by a systematic review of 11 RCTs showing reduced postoperative analgesic consumption in 73% of trials, with reduced nausea, vomiting, and shivering.[8] A 2025 narrative review further confirms magnesium’s role as an NMDA receptor antagonist that dampens central sensitization — a mechanism directly relevant to preventing acute-to-chronic pain transition in this population.[9]

The classification of PEA as potentially safe to continue represents a clinical judgment call. Meta-analyses involving 1,196 patients demonstrate significant pain reduction across all pain types with an excellent safety profile.[15][17] PEA’s mechanism (PPAR-α agonism, mast cell and glial cell modulation) does not overlap with any SPAQI-identified perioperative risk category.[16][19] However, the absence of specific perioperative studies means this recommendation carries less certainty than the SPAQI-endorsed agents.

The spine fusion caveat deserves particular emphasis — SPAQI specifically identifies spine fusion as a high-bleeding-risk procedure where postponement may be warranted if bleeding-risk supplements were not held.[1] This should be clearly communicated to patients undergoing spinal procedures.

References

Preoperative Management of Surgical Patients Using Dietary Supplements: Society for Perioperative Assessment and Quality Improvement (SPAQI) Consensus Statement. Cummings KC, Keshock M, Ganesh R, et al. Mayo Clinic Proceedings. 2021;96(5):1342-1355. doi:10.1016/j.mayocp.2020.08.016.
Preoperative Administration of Omega-3 Fatty Acids on Postoperative Pain and Acute-Phase Reactants in Patients Undergoing Roux-en-Y Gastric Bypass: A Randomized Clinical Trial. Ruiz-Tovar J, Blanca M, Garcia A, et al. Clinical Nutrition (Edinburgh, Scotland). 2019;38(4):1588-1593. doi:10.1016/j.clnu.2018.07.026.
High-Dose Vitamin D Supplementation Can Correct Hypovitaminosis D Prior to Total Knee Arthroplasty. Mouli VH, Schudrowitz N, Carrera CX, et al. The Journal of Arthroplasty. 2022;37(2):274-278. doi:10.1016/j.arth.2021.10.016.
The Role of Preoperative Vitamin D in Spine Surgery. Bajaj A, Shah RM, Goodwin AM, et al. Current Reviews in Musculoskeletal Medicine. 2023;16(2):48-54. doi:10.1007/s12178-022-09813-z.
The Effects of Cardiovascular and Orthopaedic Surgery on Vitamin Concentrations: A Narrative Review of the Literature and Mechanisms of Action. Travica N, Ried K, Hudson I, et al. Critical Reviews in Food Science and Nutrition. 2023;63(17):2929-2959. doi:10.1080/10408398.2021.1983762.
The Relation Between Acute Changes in the Systemic Inflammatory Response and Circulating Thiamine and Magnesium Concentrations After Elective Knee Arthroplasty. Maguire D, Catchpole A, Sheerins O, et al. Scientific Reports. 2021;11(1):11271. doi:10.1038/s41598-021-90591-y.
Healing From the Inside Out: Vitamins and Nutritional Strategies for Complex Regional Pain Syndrome and Chronic Postsurgical Pain. Lopez-Ruiz AA, Anastopulos FD, Trinchet LP, et al. Current Pain and Headache Reports. 2026;30(1):73. doi:10.1007/s11916-026-01508-1.
The Use of Intravenous Magnesium Sulfate on Postoperative Analgesia in Orthopedic Surgery: A Systematic Review of Randomized Controlled Trials. Peng YN, Sung FC, Huang ML, Lin CL, Kao CH. Medicine. 2018;97(50):e13583. doi:10.1097/MD.0000000000013583.
Clinical Efficacy of Magnesium in Perioperative Pain Management: A Narrative Review. Ahmadzadeh S, Wentling JG, Ford BM, et al. Current Pain and Headache Reports. 2025;29(1):117. doi:10.1007/s11916-025-01422-y.
Postoperative Pain Reduction by Pre-Emptive N-Acetylcysteine: An Exploratory Randomized Controlled Clinical Trial. Mulkens CE, Staatsen M, van Genugten L, et al. Regional Anesthesia and Pain Medicine. 2021;46(11):960-964. doi:10.1136/rapm-2021-102884.
Antinociceptive Effects of Curcumin in a Rat Model of Postoperative Pain. Zhu Q, Sun Y, Yun X, et al. Scientific Reports. 2014;4:4932. doi:10.1038/srep04932.
Boswellia Serrata: An Overall Assessment of in Vitro, Preclinical, Pharmacokinetic and Clinical Data. Abdel-Tawab M, Werz O, Schubert-Zsilavecz M. Clinical Pharmacokinetics. 2011;50(6):349-69. doi:10.2165/11586800-000000000-00000.
The Non-Surgical Management of Hip & Knee Osteoarthritis (OA) (2020). Matthew Bair MD MS, John Cody MD, Jess Edison MD, et al. Department of Veterans Affairs.
What Is Really Known About the Effects of Nicotinamide Riboside Supplementation in Humans. Damgaard MV, Treebak JT. Science Advances. 2023;9(29):eadi4862. doi:10.1126/sciadv.adi4862.
Meta-Analysis of Palmitoylethanolamide in Pain Management: Addressing Literature Gaps and Enhancing Understanding. Viña I, López-Moreno M. Nutrition Reviews. 2025;83(7):e1604-e1618. doi:10.1093/nutrit/nuae203.
Ultramicronized N-Palmitoylethanolamine Associated With Analgesics: Effects Against Persistent Pain. Nobili S, Micheli L, Lucarini E, et al. Pharmacology & Therapeutics. 2024;258:108649. doi:10.1016/j.pharmthera.2024.108649.
Efficacy of Palmitoylethanolamide for Pain: A Meta-Analysis. Artukoglu BB, Beyer C, Zuloff-Shani A, Brener E, Bloch MH. Pain Physician. 2017;20(5):353-362.
Palmitoylethanolamide for the Treatment of Pain: Pharmacokinetics, Safety and Efficacy. Gabrielsson L, Mattsson S, Fowler CJ. British Journal of Clinical Pharmacology. 2016;82(4):932-42. doi:10.1111/bcp.13020.
Palmitoylethanolamide in the Treatment of Pain and Its Clinical Application Prospects. Wang Y, Duan X, Li Z, Pan Y, Deng J. Drug Design, Development and Therapy. 2025;19:6897-6923. doi:10.2147/DDDT.S540327.

Emphasis on Education

Accurate Clinic promotes patient education as the foundation of it’s medical care. In Dr. Ehlenberger’s integrative approach to patient care, including conventional and complementary and alternative medical (CAM) treatments, he may encourage or provide advice about the use of supplements. However, the specifics of choice of supplement, dosing and duration of treatment should be individualized through discussion with Dr. Ehlenberger. The following information and reference articles are presented to provide the reader with some of the latest research to facilitate evidence-based, informed decisions regarding the use of conventional as well as CAM treatments.

For medical-legal reasons, access to these links is limited to patients enrolled in an Accurate Clinic medical program.

Should you wish more information regarding any of the subjects listed – or not listed – here, please contact Dr. Ehlenberger. He has literally thousands of published articles to share on hundreds of topics associated with pain management, weight loss, nutrition, addiction recovery and emergency medicine. It would take years for you to read them, as it did him.

For more information, please contact Accurate Clinic.

Supplements recommended by Dr. Ehlenberger may be purchased commercially online

Please read about our statement regarding the sale of products recommended by Dr. Ehlenberger.